series-a
Stage
2025
Founded
1
Investors
About
Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, with a focus on sustained efficacy and improved tolerability. They are advancing a pipeline of peptide- and protein-based metabolic therapeutics, including their lead asset ALV-100 in Phase 2 clinical development.
Explore Alveus Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.